Update of Recently (2016–2020) Designed Azepine Analogs and Related Heterocyclic Compounds with Potent Pharmacological Activities

References

• C. Kunick, C. Bleeker, C. Prühs, F. Totzke, C. Schächtele, M. H. G. Kubbutat, and A. Link, “Matrix Compare Analysis Discriminates Subtle Structural Differences in a Family of Novel Antiproliferative Agents, Diaryl-3-Hydroxy-2,3,3a,10a-Tetrahydrobenzo[b]Cycylopenta[e]Azepine-4,10(1H,5H)-Diones,” Bioorganic & Medicinal Chemistry Letters 16, no. 8 (2006): 2148–53. DOI: 10.1016/j.bmcl.2006.01.071.
   PubMed Web of Science ®Google Scholar
• T. Tsunoda, A. Yamazaki, T. Mase, and S. Sakamoto, “A Scalable Process for the Synthesis of 2-Methyl-1,4,5,6-Tetrahydroimidazo[4,5- d ][1]Benzazepine Monohydrate and 4-[(Biphenyl-2-Ylcarbonyl)Amino]Benzoic Acid: Two New Key Intermediates for the Synthesis of the AVP Antagonist Conivaptan Hydrochloride,” Organic Process Research & Development 9, no. 5 (2005): 593–8. DOI: 10.1021/op050061n.
   Web of Science ®Google Scholar
• M. Seto, N. Miyamoto, K. Aikawa, Y. Aramaki, N. Kanzaki, Y. Iizawa, M. Baba, and M. Shiraishi, “Orally Active CCR5 Antagonists as anti-HIV-1 Agents. Part 3: Synthesis and Biological Activities of 1-Benzazepine Derivatives Containing a Sulfoxide Moiety,” Bioorganic & Medicinal Chemistry 13, no. 2 (2005): 363–86. DOI: 10.1016/j.bmc.2004.10.021.
   PubMed Web of Science ®Google Scholar
• N. A. El-Sayed, F. M. Awadallah, N. A. Ibrahim, and M. T. El-Saadi, “Synthesis, anti-Inflammatory and Ulcerogenicity Studies of Some Substituted Pyrimido[1,6-a]Azepine Derivatives,” European Journal of Medicinal Chemistry 45, no. 7 (2010): 3147–54. DOI: 10.1016/j.ejmech.2010.04.005.
   PubMed Web of Science ®Google Scholar
• J. Benes, A. Parada, A. A. Figueiredo, P. C. Alves, A. P. Freitas, D. A. Learmonth, R. A. Cunha, J. Garrett, and P. Soares-da-Silva, “Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives,” Journal of Medicinal Chemistry 42, no. 14 (1999): 2582–7. DOI: 10.1021/jm980627g.
   PubMed Web of Science ®Google Scholar
• A. Link, and C. Kunick, “ d-Fused [1]benzazepines with selective in vitro antitumor activity: synthesis and structure-activity relationships,” Journal of Medicinal Chemistry 41, no. 8 (1998): 1299–305. DOI: 10.1021/jm970675l.
   PubMed Web of Science ®Google Scholar
• W. Ouyang, J. Rao, Y. Li, X. Liu, Y. Huo, Q. Chen, and X. Li, “Recent Achievements in the Rhodium‐Catalyzed Concise Construction of Medium N‐Heterocycles, Azepines and Azocines,” Advanced Synthesis & Catalysis 362, no. 24 (2020): 5576–600. DOI: 10.1002/adsc.202001040.
   Web of Science ®Google Scholar
• J. R. Heys, and S. G. Senderoff, “A New Entry into C7-Oxygenated Tetrahydro-1H-3-Benzazepines; Efficient Labeling with Carbon-14 in the Benzo Ring,” The Journal of Organic Chemistry 54, no. 19 (1989): 4702–6. DOI: 10.1021/jo00280a050.
   Web of Science ®Google Scholar
• K. Ersmark, I. Feierberg, S. Bjelic, E. Hamelink, F. Hackett, M. J. Blackman, J. Hultén, B. Samuelsson, J. Åqvist, and A. Hallberg, “Potent Inhibitors of the Plasmodium falciparum Enzymes Plasmepsin I and II Devoid of Cathepsin D Inhibitory Activity,” Journal of Medicinal Chemistry 47, no. 1 (2004): 110–22. DOI: 10.1021/jm030933g.
   PubMed Web of Science ®Google Scholar
• T. Spangenberg, “Azepanyl - Derivatives and Pharmaceutical Compositions Comprising the Same with Antiparasitic Activity” (US 9994577 B2, 2018).
   Google Scholar
• L. de, F. Diniz, J. A. Urbina, I. M. de Andrade, A. L. Mazzeti, T. A. F. Martins, I. S. Caldas, A. Talvani, I. Ribeiro, and M. T. Bahia, “Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments,” PLoS Neglected Tropical Diseases 7, no. 8 (2013): e2367. DOI: 10.1371/journal.pntd.0002367.
   PubMed Web of Science ®Google Scholar
• P. J. Hotez, E. Dumonteil, M. J. Heffernan, and M. E. Bottazzi, “Innovation for the ‘Bottom 100 Million’: Eliminating Neglected Tropical Diseases in the Americas,” in Hot Topics in Infection and Immunity in Children IX. Advances in Experimental Medicine and Biology, edited by N. Curtis, A. Fin, and A. Pollard, Vol. 764 (2013), 1–12. DOI: 10.1007/978-1-4614-4726-9_1.
   Google Scholar
• S. Sundar, and J. Chakravarty, “An Update on Pharmacotherapy for leishmaniasis,” Expert Opin Pharmacother 16, no. 2 (2015): 237–52. DOI: 10.1517/14656566.2015.973850.
   PubMed Web of Science ®Google Scholar
• M. Knockaert, K. Wieking, S. Schmitt, M. Leost, K. M. Grant, J. C. Mottram, C. Kunick, and L. Meijer, “Intracellular Targets of Paullones. Identification following Affinity Purification on Immobilized Inhibitor,” The Journal of Biological Chemistry 277, no. 28 (2002): 25493–501. DOI: 10.1074/jbc.M202651200.
   PubMed Web of Science ®Google Scholar
• A. Palma, A. F. Yépes, S. M. Leal, C. A. Coronado, and P. Escobar, “Synthesis and in Vitro Activity of New Tetrahydronaphtho[1,2-b]Azepine Derivatives against Trypanosoma cruzi and Leishmania chagasi Parasites,” Bioorganic & Medicinal Chemistry Letters 19, no. 8 (2009): 2360–3. DOI: 10.1016/j.bmcl.2008.05.013.
   PubMed Web of Science ®Google Scholar
• A. F. Yépes, A. Bahsas, P. Escobar, J. Cobo, A. Palma, J. C. Garro Martinez, and R. Enriz, “Synthesis, anti-Parasitic Activity and QSAR Study of a New Library of Polysubstituted Tetrahydronaphtho[1,2-b]Azepines,” Medicinal Chemistry Research 27, no. 10 (2018): 2239–64. DOI: 10.1007/s00044-018-2232-7.
   Web of Science ®Google Scholar
• J. Fouche, and A. Leger, “German Patent, 2031 (1971) 236,” Chem. Abstr 74, no. 1971: 76346.
   Google Scholar
• S. K. Maddili, R. Chowrasia, V. K. Kannekanti, and H. Gandham, “1,3-Di-n-Butylimidazolium Tribromide [BBim]Br3: An Efficient Recyclable Catalyst Mediated Synthesis of N-Substituted Azepines and their Biological Evaluation-Interaction Study with Human Serum Albumin,” Journal of Photochemistry and Photobiology. B, Biology 178 (2018): 101–7. DOI: 10.1016/j.jphotobiol.2017.10.028.
   PubMed Web of Science ®Google Scholar
• A. Sharma, D. Kishore, and B. Singh, “An Expedient Method for the Synthesis of 1,2,4-Triazolo-Fused 1,5-Benzodiazepine, 1,5-Benzoxazepine, and 1,5-Benzothiazepine Scaffolds: A Novel Seven-Membered Ring System of Biological Interest,” Journal of Heterocyclic Chemistry 55, no. 3 (2018): 586–92. DOI: 10.1002/jhet.3060.
   Web of Science ®Google Scholar
• S.A. Demchenko, O.E. Yadlovskyi, L.S. Bobkova, А.M. Demchenko, Synthesis and Antiviral Activity of Derivatives of 1-(41-Chlorophenyl)-3-Aryl-3-Hydroxy-2,5,6,7,8,9- Hexahydro-3Н-Imidazo[1,2-а]Azepinium for Flu A H1N1 California/07/2009 and Flu A H3N2 Brisbane/10/2007, Pharmacology and Drug Toxicology 6 (2018) 44–51. http://nbuv.gov.ua/UJRN/ flt _2018_6_7
   Google Scholar
• S. A. Demchenko, T. A. Bukhtiarova, L. S. Bobkova, and A. M. Demchenko, “Synthesis and Antiviral Activity of Derivatives of 1- (2,3-Dihydrobenzo | 1,4 | Dioxan-6-yl) -3-Aryl-3-Hydroxy-2,5,6,7,8,9- 3H-Imidazo | 1,2-a | Azepine and Amizon Substances,” Pharmacology and Drug Toxicology 1 (2018): 26–31.
   Google Scholar
• P. Bonaventure, C. Dugovic, M. Kramer, P. de Boer, J. Singh, S. Wilson, K. Bertelsen, J. Di, J. Shelton, L. Aluisio, et al, “Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder,” Journal of Pharmacology and Experimental Therapeutics 342, no. 2 (2012): 429–40. DOI: 10.1124/jpet.112.193995.
   PubMed Web of Science ®Google Scholar
• P. J. Lovell, S. M. Bromidge, S. Dabbs, D. M. Duckworth, I. T. Forbes, A. J. Jennings, F. D. King, D. N. Middlemiss, S. K. Rahman, D. V .Saunders, et al, “ A novel, Potent, and Selective 5-HT(7) Antagonist: (R)-3-(2-(2-(4-Methylpiperidin-1-yl)Ethyl)Pyrrolidine-1-Sulfonyl) Phen ol (SB-269970)),” Journal of Medicinal Chemistry 43, no. 3 (2000): 342–5. DOI: 10.1021/jm991151j.
   PubMed Web of Science ®Google Scholar
• C. A. Dvorak, D. A. Rudolph, D. Nepomuceno, L. Dvorak, B. Lord, I. Fraser, P. Bonaventure, T. Lovenberg, and N. I. Carruthers, “Discovery and SAR Studies of 2-Alkyl-3-Phenyl-2,4,5,6,7,8-Hexahydropyrazolo[3,4-d]Azepines as 5-HT7/2 Inhibitors Leading to the Identification of a Clinical Candidate,” Bioorganic & Medicinal Chemistry Letters 31 (2021): 127669. DOI: 10.1016/j.bmcl.2020.127669.
   PubMed Web of Science ®Google Scholar
• F. G. Ashby, V. Valentin, and S. von Meer, “Differential Effects of Dopamine-Directed Treatments on Cognition,” Neuropsychiatric Disease and Treatment 29 (2015): 1859–75. DOI: 10.2147/NDT.S65875.
   Google Scholar
• Q. Mu, K. Johnson, P. S. Morgan, E. L. Grenesko, C. E. Molnar, B. Anderson, Z. Nahas, F. A. Kozel, S. Kose, M. Knable, et al, “A Single 20 mg Dose of the Full D1 Dopamine Agonist Dihydrexidine (DAR-0100) Increases Prefrontal Perfusion in Schizophrenia,” Schizophrenia Research 94, no. 1-3 (2007): 332–41. DOI: 10.1016/j.schres.2007.03.033.
   PubMed Web of Science ®Google Scholar
• N. H. Mutschler, and J. Bergman, “Effects of Chronic Administration of the D1 Receptor Partial Agonist SKF 77434 on Cocaine Self-Administration in Rhesus Monkeys,” Psychopharmacology 160, no. 4 (2002): 362–70. DOI: 10.1007/s00213-001-0976-z.
   PubMed Web of Science ®Google Scholar
• R. Giri, I. Alberts, and W. W. Harding, “Synthesis, Pharmacological Evaluations, and Molecular Docking Studies on a New 1,3,4,11b-Tetrahydro-1H-Fluoreno[9,1-cd]Azepine Framework: Rigidification of D1 Receptor Selective 1-Phenylbenzazepines and Discovery of a New 5-HT6 Receptor Scaffold,” Chemical Biology & Drug Design 96, no. 2 (2020): 825–35. DOI: 10.1111/cbdd.13691.
   PubMed Web of Science ®Google Scholar
• S. Celanire, L. Tang, N. J. Liverton, and P. Jones, “Tetrahydropyrazolo [ 3,4-b) Azepine Derivatives and their use as Allosteric Modulators of Metabotropic Glutamate Receptors” (US9765091B2, 2011).
   Google Scholar
• H. E. Scharfman, “The Neurobiology of Epilepsy,” Current Neurology and Neuroscience Reports 7, no. 4 (2007): 348–54. DOI: 10.1007/s11910-007-0053-z.
   PubMed Web of Science ®Google Scholar
• C. E. Stafstrom, “Epilepsy: A Review of Selected Clinical Syndromes and Advances in Basic Science,” Journal of Cerebral Blood Flow and Metabolism : official Journal of the International Society of Cerebral Blood Flow and Metabolism 26, no. 8 (2006): 983–1004. DOI: 10.1038/sj.jcbfm.9600265.
   PubMed Web of Science ®Google Scholar
• M. J. Brodie, “Monotherapy Trials: Prerequisite Data,” Epilepsy Research 45, no. 1-3 (2001): 61–4. DOI: 10.1016/S0920-1211(01.)00218-2.
   PubMed Web of Science ®Google Scholar
• A. Reimers, “New Antiepileptic Drugs and Women,” Seizure 23, no. 8 (2014): 585–91. DOI: 10.1016/j.seizure.2014.05.004.
   PubMed Web of Science ®Google Scholar
• H. Kaur, B. Kumar, and B. Medhi, “Antiepileptic Drugs in Development Pipeline: A Recent Update,” ENeurologicalSci 4 (2016): 42–51. DOI: 10.1016/j.ensci.2016.06.003.
   PubMedGoogle Scholar
• S. N. Sirakanyan, D. Spinelli, A. Geronikaki, and A. A. Hovakimyan, “On the Reactivity of Pyrido[3′,2′:4,5]Furo(Thieno)[3,2-d]Pyrimidin-7(8)-Ones with Some Alkyl Mono- and di-Halides: synthesis of New Heterocyclic Systems Containing Thiazolo[3,2-a]Pyrimidine and Pyrimido[2,1-b]Thiazine Moiety,” Tetrahedron 71, no. 40 (2015): 7638–46. DOI: 10.1016/j.tet.2015.07.069.
   Web of Science ®Google Scholar
• S. N. Sirakanyan, A. A. Ovakimyan, A. S. Noravyan, N. S. Minasyan, I. A. Dzhagatspanyan, I. M. Nazaryan, and A. G. Akopyan, “Synthesis and Neurotropic Activity of 8-Amino Derivatives of Condensed Thieno[3,2-d]- and Furo[3,2-d]Pyrimidines,” Pharmaceutical Chemistry Journal 47, no. 12 (2014): 655–9. DOI: 10.1007/s11094-014-1026-6.
   Web of Science ®Google Scholar
• S. N. Sirakanyan, A. Geronikaki, D. Spinelli, R. G. Paronikyan, I. A. Dzhagatspanyan, I. M. Nazaryan, A. H. Akopyan, and A. A. Hovakimyan, “Pyridofuropyrrolo[1,2-a]Pyrimidines and Pyridofuropyrimido[1,2-a]Azepines: new Chemical Entities (NCE) with Anticonvulsive and Psychotropic Properties,” RSC Advances 6, no. 38 (2016): 32234–44. DOI: 10.1039/C6RA02581A.
   Web of Science ®Google Scholar
• G. Guerrini, A. Costanzo, G. Ciciani, F. Bruni, S. Selleri, C. Costagli, F. Besnard, B. Costa, C. Martini, G. de Siena, et al, “Benzodiazepine Receptor Ligands. 8: Synthesis and Pharmacological Evaluation of New Pyrazolo[5,1-c] [1,2,4]Benzotriazine 5-Oxide 3- and 8-Disubstituted: High Affinity Ligands Endowed with Inverse-Agonist Pharmacological Efficacy,” Bioorganic & Medicinal Chemistry 14, no. 3 (2006): 758–75. DOI: 10.1016/j.bmc.2005.08.058.
   PubMed Web of Science ®Google Scholar
• R. Kumar, and Y. C. Joshi, “Synthesis and Antimicrobial, Antifungal and Anthelmintic Activities of 3h-1,5-Benzodiazepine Derivatives,” Journal of the Serbian Chemical Society 73, no. 10 (2008): 937–43. DOI: 10.2298/JSC0810937K.
   Web of Science ®Google Scholar
• S. J. R. Rajarao, B. Platt, S. J. Sukoff, Q. Lin, C. N. Bender, B. W. Nieuwenhuijsen, R. H. Ring, L. E. Schechter, S. Rosenzweig-Lipson, and C. E. Beyer, “Anxiolytic-like Activity of the Non-Selective Galanin Receptor Agonist, Galnon,” Neuropeptides 41, no. 5 (2007): 307–20. DOI: 10.1016/j.npep.2007.05.001.
   PubMed Web of Science ®Google Scholar
• Y.-P. Shao, R.-B. Han, H.-F. Wu, and F.-Y. Piao, “Synthesis and Anticonvulsant Activity of Some Novel 7-(Benzylamino) -1H-Benzo[b][1,4]Diazepine-2,4(3H, 5H)-Dione Derivatives,” Medicinal Chemistry Research 27, no. 2 (2018): 642–52. DOI: 10.1007/s00044-017-2089-1.
   Web of Science ®Google Scholar
• F.-Y. Piao, Y.-Z. Xie, W.-B. Zhang, W. Zhang, and R.-B. Han, “High-Yield Method for the Preparation of 1,3,4,5-Tetrahydro-7-Methoxy-2 H -1-Benzazepin-2-One with Excellent Regio- and Stereoselectivity,” Synthetic Communications 43, no. 14 (2013): 1920–30. DOI: 10.1080/00397911.2012.680571.
   Web of Science ®Google Scholar
• C.-X. Wei, W. Zhang, Z.-S. Quan, R.-B. Han, R.-S. Jiang, and F.-Y. Piao, “Synthesis, Anticonvulsant Evaluation of 2,3,4,5-Tetrahydro-7-Alkoxy-1H-2-Benzazepin-1-Ones,” Letters in Drug Design & Discovery 6, no. 7 (2009): 548–53. DOI: 10.2174/157018009789108231.
   Web of Science ®Google Scholar
• M. G. Craske, and M. B. Stein, “Anxiety,” The Lancet 388, no. 10063 (2016): 3048–59. DOI: 10.1016/S0140-6736.(16)30381-6.
   PubMed Web of Science ®Google Scholar
• R. B. Lydiard, “The Role of GABA in Anxiety Disorders,” Journal of Clinical Psychiatry 64 (2003): 21–27.
   PubMed Web of Science ®Google Scholar
• D. K. Mahapatra, D. Das, R. S. Shivhare, and K. M. Dadure, “Transforming Murrayanine-Chalcone into Corresponding 3H-Benzo[b] [1,4] Diazepine Derivatives: Accessing the anti-Anxiety Effect by Inhibition of Locomotor Activity,” Acta Scientific Pharmaceutical Sciences 2 (2018): 40–4.
   Google Scholar
• J. R. Atack, “GABAA Receptor Subtype-Selective Modulators. I. α2/α3-Selective Agonists as Non-Sedating Anxiolytics,” Current Topics in Medicinal Chemistry 11 (2011): 1176–202. DOI: 10.2174/156802611795371350.
   PubMed Web of Science ®Google Scholar
• S. A. Demchenko, O. E. Yadlovskyi, O. v Yudina, I. I. Tubaltseva, YuA. Fedchenkova, L. S. Bobkova, and АM. Demchenko, “Synthesis and Anxiolytic Activity of 3-Aryl-1-(41methoxyphenyl)-1-(6,7,8,9-Tetrahydro5h -[1,2,4] Triazolo[4,3-a]Azepine-3-yl-Methyl)- Urea Derivatives,” Pharmacology and Drug Toxicology 14 (2020): 88–96. DOI: 10.33250/14.02.088.
   Google Scholar
• S. A. Hrnack, and F. A. Barber, “Managing the Pain of Knee Osteoarthritis,” The Physician and Sportsmedicine 42, no. 3 (2014): 63–70. DOI: 10.3810/psm.2014.09.2077.
   PubMed Web of Science ®Google Scholar
• P. Pirlamarla, and R. M. Bond, “FDA Labeling of NSAIDs: Review of Nonsteroidal anti-Inflammatory Drugs in Cardiovascular Disease,” Trends in Cardiovascular Medicine 26, no. 8 (2016): 675–80. DOI: 10.1016/j.tcm.2016.04.011.
   PubMed Web of Science ®Google Scholar
• P. Rao, and E. E. Knaus, “Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond,” Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques 11, no. 2 (2008): 81s–110s. DOI: 10.18433/J3T886.
   PubMed Web of Science ®Google Scholar
• S. A. Demchenko, H. O. Yeromina, L. O. Perekhoda, T. A. Bukhtiarova, L. S. Bobkova, and A. M. Demchenko, “Synthesis and Anаlgеsic Properties of (3-Allyl-4-Aryl-3H-Thiazol-2-Ylidene)-[4-(6,7,8,9-Tetrahydro-5H-[1,2,4]Triazolo[4,3-a]Azepin-3-yl)Phenyl]Amine Derivatives,” Farmatsevtychnyi Zhurnal 1, no. 1 (2018): 67–73. DOI: 10.32352/0367-3057.1.17.09.
   Google Scholar
• S. Demchenko, N. Chalenko, T. Bukhtiarova, N. Seredynska, L. Bobkova, and O. Yadlovsky, “Synthesis and Analgesic Activity of 6,7,8,9-Tetrahydro-5H- [1,2,4] Triazolo [4,3-a]Azepines,” Pharmacology and Drug Toxicology 60 (2018): 25–31.
   Google Scholar
• C. Guo, L. Wang, X. Li, S. Wang, X. Yu, K. Xu, Y. Zhao, J. Luo, X. Li, B. Jiang, et al, “Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer,” Journal of Medicinal Chemistry 62, no. 6 (2019): 3051–67. DOI: 10.1021/acs.jmedchem.8b01946.
   PubMed Web of Science ®Google Scholar
• L.-W. Wang, H.-J. Su, S.-Z. Yang, S.-J. Won, and C.-N. Lin, “New Alkaloids and A Tetraflavonoid from Cephalotaxus wilsoniana,” Journal of Natural Products 67, no. 7 (2004): 1182–5. DOI: 10.1021/np0498657.
   PubMed Web of Science ®Google Scholar
• H. Morita, M. Yoshinaga, and J. Kobayashi, “Cephalezomines G, H, J, K, L, and M, New Alkaloids from Cephalotaxus Harringtonia Var. nana,” Tetrahedron 58, no. 27 (2002): 5489–95. DOI: 10.1016/S0040-4020(02.)00521-5.
   Web of Science ®Google Scholar
• S. Li, X. Li, T. Zhang, M. O. Kamara, J. Liang, J. Zhu, and F. Meng, “Design, Synthesis and Biological Evaluation of Homoerythrina Alkaloid Derivatives Bearing a Triazole Moiety as PARP-1 Inhibitors and as Potential Antitumor Drugs,” Bioorganic Chemistry 94 (2020): 103385. DOI: 10.1016/j.bioorg.2019.103385.
   PubMed Web of Science ®Google Scholar
• R. H. Nelson, “Hyperlipidemia as a Risk Factor for Cardiovascular Disease,” Prim Care 40, no. 1 (2013): 195–211. DOI: 10.1016/j.pop.2012.11.003.
   PubMed Web of Science ®Google Scholar
• S. E.-S. Barakat, M. A A. El-Zahabi, A. A. Abdel-Rahman, A. H. Bayomi, H. E. Ali, M. A. Amin, M. A. El-Zahabi, and S. Barakat, “Synthesis of Certain New Dibenz[c,e]Azepine-5,7-Diones of Expected Antihyperlipidemic Activity,” Journal of King Abdulaziz University-Medical Sciences 14, no. 4 (2007): 3–17. DOI: 10.4197/Med.14-4.1.
   Google Scholar
• M. Verma, A. K. Gupta, and R. N. Thakur, “Synthesis and Antihyperlipidemic Activity of Dibenz[c,e]Azepine-5,7-Dione Derivatives in Triton WR-1339-Induced Hyperlipidemic Rats,” Journal of Drug Delivery and Therapeutics 8, no. 2 (2018): 129–35. DOI: 10.22270/jddt.v8i2.1684.
   Google Scholar
• Y. Ohsawa, and N. Hirasawa, “The Antagonism of Histamine H1 and H4 Receptors Ameliorates Chronic Allergic Dermatitis via anti-Pruritic and Anti-Inflammatory Effects in NC/Nga Mice,” Allergy 67, no. 8 (2012): 1014–22. DOI: 10.1111/j.1398-9995.2012.02854.x.
   PubMed Web of Science ®Google Scholar
• T. Somma, L. Cinci, G. Formicola, A. Pini, R. Thurmond, M. Ennis, D. Bani, and E. Masini, “A Selective Antagonist of Histamine H4 Receptors Prevents Antigen-Induced Airway Inflammation and Bronchoconstriction in guinea Pigs: Involvement of Lipocortin-1,” British Journal of Pharmacology 170, no. 1 (2013): 200–13. DOI: 10.1111/bph.12264.
   PubMed Web of Science ®Google Scholar
• I. Berrebi-Bertrand, X. Billot, T. Calmels, M. Capet, S. Krief, O. Labeeuw, J.-M. Lecomte, N. Levoin, X. Ligneau, P. Robert, and J.-C. Schwartz, “6,11-Dihydro-5h-benzodimidazo1,2- aiazepines Derivatives as Histamine h4 Receptor Ligands” (US 9.255,101 B2, 2016).
   Google Scholar
• B. E. Blass, “Triazolo-Azepine Inhibitors of γ-Secretase and Their Methods of Use,” ACS Medicinal Chemistry Letters 10, no. 9 (2019): 1243–4. DOI: 10.1021/acsmedchemlett.9b00327.
   PubMedGoogle Scholar
• S. P. Kollur, J. O. Castro, J. Frau, and D. Glossman-Mitnik, “Chemical Synthesis, Spectroscopic Studies, Chemical Reactivity Properties and Bioactivity Scores of an Azepin-Based Molecule,” Journal of Molecular Structure 1180 (2019): 300–6. DOI: 10.1016/j.molstruc.2018.11.061.
   Web of Science ®Google Scholar